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ABSTRACT:
The metastasis-inducing protein S100A4 was found to be a prognostic indicator 
for the development of metachronous metastases. S100A4 expression levels correlate 
with the formation of human colorectal cancer metastases and shorter patients’ 
survival. Inhibition of S100A4 expression in patients might therefore result in 
decreased metastasis formation and prolonged survival. In the present study, we 
used shRNA expression plasmids to inhibit S100A4 expression in the colorectal cancer 
cell lines HCT116, SW620 and DLD-1. Cell lines with reduced S100A4 expression 
showed reduced cell migration and invasion in vitro. The knock-down of S100A4 
expression also led to significantly diminished formation of liver metastases 
when intrasplenically transplanted in mice (P = 0.004). We then focused on the 
therapeutic potential of systemically applied shRNA expression plasmids acting 
on S100A4 via repeated hydrodynamics-based tail vein injection of plasmid DNA. 
Mice, intrasplenically transplanted with HCT116 cells and treated systemically with 
S100A4-shRNA plasmids, showed a decrease of S100A4 and MMP9 expression levels, 
resulting in significantly reduced liver metastases (P = 0.005). In summary, we show 
for the first time the intratumoral knock-down of S100A4 via systemic application of 
S100A4-shRNA plasmid DNA, which restricts metastasis formation in a xenografted 
mouse model of colorectal cancer.
INTRODUCTION
Colorectal cancer is the third most common type of 
cancer worldwide, with more than 1.2 million new cases 
in the year 2008, and the second leading cause of cancer-
related deaths in the Western world [1]. Although the 
5-year-survival rate of patients diagnosed with colorectal 
cancer at an early stage is about 90%, it drops to 65% 
if regional lymph node metastases occur, and decreases 
to less than 10% if the patient is diagnosed with distant 
metastases [2].
The transformation of normal colon tissue to 
malignant cancer is caused by deregulated expression 
of both cancer promoting and inhibiting factors, 
often affecting tissue specific signaling pathways. 
Constitutively active Wnt/β‑catenin signaling interferes 
with cell differentiation and promotes uncontrolled 
cell proliferation [3]. Consistently, almost all cases of 
colorectal cancer contain mutations in the Wnt/β‑catenin 
signaling pathway, leading to sustained expression of its 
target genes [4].
One of the target genes of β‑catenin regulated 
transcription is S100A4, also known as mts1 [5]. 
Overexpression of S100A4 in colorectal cancer tissue 
correlates with higher metastasis formation and is 
associated with a decrease of the patients’ survival 
rate [6],[7]. Although no increased tumor formation was 
found in S100A4 transgenic mice, metastasis formation 
was highly promoted, when crossed with mice that form 
tumors spontaneously. In turn, genomic knock-out of 
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Figure 1:S100A4-shRNA reduces S100A4 expression and cellular motility in HCT116. (A) qRT-PCR analysis of S100A4 
mRNA and Western blot analysis of S100A4 protein level of HCT116-LUC, HCT116-LUC-shNC, and HCT116-LUC-shS100A4 cells. 
Data represent mean S100A4 / G6PDH mRNA ratios (n = 4) ± SD. Results of HCT116-LUC cells were set to 100%. Equal loading 
at Western blot analysis of S100A4 protein in the cell lines was confirmed by GAPDH protein detection. (B) Immunocytochemistry 
staining of HCT116-LUC, HCT116-LUC-shNC, and HCT116-LUC-shS100A4 cells using anti-S100A4 antibody. Nuclei were stained with 
hematoxylin. Scale bar represents 50 µm. (C) Real time monitoring of cellular migration with the xCELLigence DP system. The signals 
of HCT116-LUC, HCT116-LUC-shNC and HCT116-LUC-shS100A4 cells were normalized at 2 hours. Data indicate mean (n = 3) ± SD. 
(D) Differences in cell index, due to cell migration over time, were quantified by integrating the normalized curves between 2 hours and 
8 hours. Results of HCT116-LUC-shNC and HCT116-LUC-shS100A4 cells were normalized to HCT116-LUC cells. Data represent mean 
(n = 3) ± SD. (E) Wound healing assay for directed migration of HCT116-LUC, HCT116-LUC-shNC and HCT116-LUC-shS100A4 cells. 
A 0.3 mm scratch was set in a semi confluent cell layer and cells were monitored until day 4. Representative images were taken to illustrate 
the closing of the wound. (F) Quantification of migrated HCT116‑LUC, HCT116‑LUC‑shNC and HCT116‑LUC‑shS100A4 cells, by image 
analysis of the scratch. Data represent mean densities in the cell layer wound (n = 3) ± SD. (G) Real time monitoring of cell invasion. The 
signals of the cell lines HCT116-LUC, HCT116-LUC-shNC and HCT116-LUC-shS100A4 were normalized at 12 hours. Data represent 
mean (n = 3) ± SD. (H) Differences in cell index, due to Matrigel invasion over time, were quantified by calculating the area under the 
normalized curves between 12 hours and 36 hours. Results of HCT116-LUC-shNC and HCT116-LUC-shS100A4 cells were normalized to 
HCT116-LUC cells. Data represent mean (n = 3) ± SD.
Oncotarget 2012; 3: 783-797785www.impactjournals.com/oncotarget
S100A4 strongly decreased the metastasis formation of 
highly metastasizing cancer cells in mice [8–10]. The 
ability of S100A4 to promote metastasis formation is 
mainly based on the variety of its interaction partners, 
which are involved in cellular migration, invasion, 
adhesion or angiogenesis [11–13]. Additionally, S100A4 
can regulate the interplay of matrix metalloproteinases 
(MMPs) and their endogenous inhibitors (TIMPs), which 
are involved in invasion processes [14–16].
The inhibition of S100A4 expression or function 
can reduce the malignancy caused by enhanced S100A4 
protein levels and, if used in clinical application, may 
increase the metastasis free survival of cancer patients. 
Several studies have reported strategies to decrease 
S100A4 expression in cell lines and tumor tissue. Some 
focused on the inhibition of the Wnt/β‑catenin signaling 
activity with small molecules to reduce S100A4 at the 
transcriptional level [17–20]. Others focused on the 
posttranscriptional hydrolysis of S100A4 mRNA in cell 
lines, by transfection of catalytically active ribozymes 
or employing the RNA interference mechanism, with 
short interfering (si) RNA or the expression of short 
hairpin (sh) RNA directed against the S100A4 mRNA 
sequence [21–23].
In the present study, we used gene specific shRNA 
to inhibit S100A4 expression in the colorectal cancer cell 
lines HCT116, SW620, and DLD-1, resulting in reduced 
cell motility in vitro and, for HCT116, reduced metastasis 
formation after xenograft transplantation in vivo. For the 
first time, we performed systemic, hydrodynamics‑based 
delivery of S100A4-shRNA expression plasmids thereby 
decreasing the S100A4 expression in the tumor tissue 
of xenografted mice for colorectal cancer, which led to 
reduced metastasis formation in vivo.
RESULTS
Down-regulation of S100A4 by stable, plasmid 
based shRNA expression inhibits cellular 
migration and invasion in vitro.
We began our S100A4 knock down studies using 
HCT116-LUC, HCT116-LUC-shNC and HCT116-
LUC-shS100A4 cells. HCT116-LUC cells also express 
firefly luciferase. HCT116‑LUC‑shNC and HCT116‑
LUC-shS100A4 cells were additionally transfected 
with either an unrelated control shRNA-sequence 
(negative control, NC) or an S100A4 specific shRNA. 
S100A4 mRNA level showed a significant reduction to 
13% in HCT116-LUC-shS100A4 cells, compared to 
HCT116-LUC and HCT116-LUC-shNC cells, respectively 
(P < 0.001). Western blotting of total cell lysates and 
immunostaining against S100A4 confirmed the decrease of 
endogenous S100A4 expression level in S100A4-shRNA 
transfected cells, compared to the respective control cells 
(Figure 1A). Immunocytochemistry of HCT116-LUC, 
Table 1: Comparison of body weights, organ weights and bioluminescence signal intensities 
of spleens (tumors) and livers (metastases) of xenografted mice.
Transplanted cell line 1
Body 
weight
(gram)
mean ± SD
Spleen 
weight
(gram)
mean ± SD
Liver 
weight
(gram)
mean ± SD
Bioluminescence
 signal intensity
mean ± SD
Spleen Liver
HCT116-LUC-shNC (n = 8)
HCT116-LUC-shS100A4 (n = 8)
20.8 ± 1.6
19.3 ± 0.9
0.05 ± 0.01
0.06 ± 0.03
1.2 ± 0.1
1.1 ± 0.1
18.1 ± 11.3
15.7 ± 12.1
13.1 ± 11.9
0.8 ± 0.8
n.s. n.s. n.s. n.s. P = 0.035
Transplanted cell line 1 Plasmid (t.v.i.) 2
HCT116-LUC
p-shNC (n = 8)
p-shS100A4 (n 
= 8)
18.5 ± 2.0
18.4 ± 1.9
0.18 ± 0.07
0.20 ± 0.07
1.2 ± 0.1
1.1 ± 0.2
16,4 ± 8,4
14,1 ± 8,2
21,9 ± 20,8
4,5 ± 4,3
n.s. n.s. n.s. n.s. P = 0.032
Abbreviations: SD, standard deviation; LUC, firefly luciferase; shNC, negative control shRNA; shS100A4, S100A4 
specific shRNA; t.v.i., tail vein injection; 1 xenografted mice with intrasplenic transplantation of indicated cell lines; 
2 continued systemic application of shRNA expression plasmids, via tail vein injection; data represent mean ± SD; 
statistical analysis of groups was done by Mann-Whitney-Rank-Sum-Test.
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Figure 2: Reduction of cellular migration in SW620 and DLD-1 colorectal cancer cell lines after S100A4-shRNA 
transfection. qRT-PCR analysis of S100A4 mRNA and Western blot analysis of protein level in parental SW620, SW620-shNC and 
SW620‑shS100A4 cells (A), and in parental DLD‑1, DLD‑1‑shNC and DLD‑1‑shS100A4 cells (B), respectively. Data represent mean 
S100A4 / G6PDH mRNA ratios (n = 4) ± SD. Results of parental cells were set to 100%. Equal loading at Western blot analysis of S100A4 
protein in the cell lines was confirmed by GAPDH protein detection. (C,D) Boyden Chamber assay of cell migration. Data represent the 
number of migrated parental and shRNA transfected cell lines derived from SW620 and DLD-1, normalized to the parental SW620 and 
DLD-1 cell lines, respectively (as mean (n = 3) ± SD). (E,F) Doubling times of parental and shRNA transfected cell lines derived from 
SW620 and DLD-1, respectively, were determined by MTT assays. Data represent mean values (n = 3) ± SD.
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HCT116-LUC-shNC and HCT116-LUC-shS100A4 
cells demonstrated a high expression of S100A4 in 
HCT116-LUC and HCT116-LUC-shNC cells, but a strong 
S100A4 protein reduction in HCT116-LUC-shS100A4 
cells (Figure 1B).
S100A4 has previously been linked to enhanced 
tumor migration and formation of metastasis of colorectal 
cancer [6],[24],[25]. Therefore, we analyzed the ability 
of these cells to migrate through porous membranes with 
the xCELLigence system, which allows real time data 
recording of cellular processes. In the xCELLigence-based 
assay, migrated cells attach on the bottom side of the 
membrane and increase the electrical impedance at the 
electrodes. HCT116-LUC-shS100A4 cells showed a 
delay of the signal increase of almost 3 hours and a lower 
signal increase than the control cells HCT116-LUC and 
HCT116-LUC-shNC (Figure 1C). We integrated the 
area under the signal curves of independent experiments 
and observed a significant reduction of migrating 
HCT116-LUC-shS100A4 cells to 49% (P = 0.031) 
compared to the control cell lines HCT116-LUC and 
HCT116-LUC-shNC (Figure 1D).
Figure 3: Stable S100A4 knock down in transplanted HCT116-LUC cells reduces metastasis formation in vivo. The 
cell lines HCT116-LUC-shNC and HCT116-LUC-shS100A4 were transplanted into the spleen of NOD/SCID mice (n = 8 per group). (A) 
In vivo images of a representative animal of each group in lateral and dorsal position, respectively, depicted at days 7, 14, and 28 after 
transplantation. Luminescence and bright field images were combined as an overlay picture. The color bar indicates the signal strength 
after 5 minutes exposure time. (B) After sacrificing, spleens and livers were removed of each animal and ex vivo imaging was performed 
separately. The spleens and livers depicted originate from the representative animals shown in (A). The color bar indicates the signal 
strength after 20 seconds exposure time. (C) The level of metastasis was evaluated by scoring. The score for each liver was calculated 
as the sum of the volumes of the individual metastases. Data represent the mean liver metastasis score (n = 8) ± SD of each group. (D) 
Quantification of ex vivo bioluminescence intensities of isolated livers. Data represent mean intensities (n = 8) ± SD of each group. (E,F) 
Ratios of S100A4 / G6PDH mRNA and MMP9 / GAPDH mRNA in primary tumor tissues were determined by qRT-PCR. Data represent 
mean (n = 8) ± SD. Results of transplanted HCT116-LUC-shNC cells were set to 100%.
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Figure 4: Systemic application of S100A4-shRNA-plasmids reduced metastasis formation of intrasplenically 
transplanted HCT116-LUC cells in vivo. (A) Plasmid concentration in blood after single tail vein injection. Blood samples were 
taken before and 5 minutes, 30 minutes, and 1, 2, 4 and 24 hours after a single tail vein injection (t.v.i) of ten µg shRNA‑expression plasmid, 
supplemented with 2 µg aurintricarbolic acid (ATA), in 200 µl PBS into NOD/SCID mice. Plasmid copy numbers per µg of total DNA were 
determined by qPCR. Data represent mean (n = 5) ± SD. Randomly selected groups of NOD/SCID mice with intrasplenically transplanted 
HCT116-LUC cells (n = 8 per group) were treated with systemically applied shRNA-plasmids (negative control and shS100A4, respectively) 
via repeated tail vein injection. (B) In vivo images of representative mice of each group at lateral and dorsal position, depicted at days 11, 
19, and 27 after transplantation. Luminescence and bright field images were combined as overlay pictures. The color bar indicates the signal 
strength after 5 minutes exposure time. (C) After sacrificing, spleens and livers were removed of each animal and ex vivo imaging was 
performed separately. The spleens and livers depicted originate from the representative animals shown in (B). The color bar indicates the 
signal strength after 20 seconds exposing time. (D) The level of metastasis was evaluated by scoring. The score for each liver was calculated 
as the sum of the volumes of the individual metastasis. Data represent the mean liver metastasis score (n = 8) ± SD of each group. (E) 
Quantification of ex vivo bioluminescence intensities of isolated livers. Data represent mean intensities (n = 8) ± SD of each group. (F,G) 
Copy number of each shRNA expression plasmid per µg of total DNA, isolated from spleen and liver (respectively) of each animal and 
quantified via amplification of a plasmid backbone specific amplicon. Data represent mean (n=8) ± SD, of each group.
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The directed cellular migration was evaluated by 
closing an applied scratch in a cell layer, documented 
daily until day 4. HCT116-LUC-shS100A4 cells showed 
a strong delay in wound closure compared to the control 
cell lines (Figure 1E). The closure of the wound was 
quantified by image analysis, resulting in a decrease of 
41% in HCT116-LUC-shS100A4 cells (P < 0.001), 
compared to the control cell lines HCT116-LUC and 
HCT116-LUC-shNC (Figure 1F).
Beside increased migration, cancer cells have to 
pass through an intercellular matrix barrier to invade 
adjacent tissues and form distant metastases. We measured 
the ability of the cell lines to penetrate an extracellular 
matrix (ECM) like structure by adding a layer of Matrigel 
on top of the membranes. Using the xCELLigence 
system, S100A4-shRNA transfected cells showed a lower 
increase of the cell index after 24 hours (Figure 1G). 
The integration of the curves showed a decrease to 55% 
(P = 0.035), compared to the control cells (Figure 1H). 
The xCELLigence-based in vitro motility assays were 
confirmed by classical Boyden chamber assays for cell 
migration and invasion (Figure S1A,B).
We also analyzed the proliferative abilities 
of HCT116-LUC, HCT116-LUC-shNC, and 
HCT116-LUC-shS100A4 cells. However, neither the 
doubling time nor the ability to form colonies in soft agar 
differed significantly (Figure S1C,D).
We verified the reduction of cellular motility 
after S100A4 knock-down in the colorectal cancer cell 
lines SW620 and DLD-1. We generated stably shRNA 
transfected clones thereof, SW620-shNC and SW620-
shS100A4, as well as DLD-1-shNC and DLD1-shS100A4. 
In SW620-shS100A4 and DLD-1-shS100A4 cells, 
S100A4 mRNA levels were reduced to 17% (P = 0.004) 
and 28% (P = 0.017), respectively, compared to the 
respective control cell lines containing either no or control 
shRNA (Figure 2A,B). By counting migrated cells in the 
Boyden chamber assay, we observed a reduction in cell 
migration in the cell lines SW620-shS100A4 to 53% 
(P = 0.030), and DLD-1-shS100A4 to 59% (P = 0.041), 
Figure 5: Tail vein injection of S100A4-shRNA-plasmids reduces S100A4 and MMP9 expression in tumors and 
metastases. Ratios of S100A4 mRNA and MMP9 mRNA to house-keeping gene expression were determined by qRT-PCR. Data represent 
mean (n = 8) ± SD. Results of treatment with shNC expression plasmids were set to 100%. (A) S100A4 / G6PDH mRNA expression of 
primary tumors; (B) S100A4 / G6PDH mRNA expression of liver metastases; (C) MMP9 / GAPDH mRNA expression of primary tumors; 
(D) MMP9 / GAPDH mRNA expression of liver metastases. Immunhistochemistry staining of representative spleen tumor sections of each 
group for S100A4 (E) and MMP9 (F), respectively. Nuclei were stained with hematoxylin. The scale bar represents 100 µm.
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compared to the respective control cells (Figure 2C,D). No 
change in the doubling time of the cell lines derived from 
SW620 and DLD-1 was observed (Figure 2E,F).
Transplantation of S100A4 knock-down cells 
reduces metastasis formation in mice.
Our results showed a clear decrease in the 
metastatic potential of colorectal cancer cells, when stably 
transfected with S100A4-shRNA expression plasmids. 
To evaluate the anti-metastatic effect of S100A4 knock-
down in vivo, the cell lines HCT116-LUC-shNC and 
HCT116-LUC-shS100A4 were transplanted into the 
spleens of female NOD/SCID mice (n = 8, each group). 
The ability of the cells to form metastases in the liver 
was examined by in vivo bioluminescence imaging 
of animals and ex vivo scoring of visible metastases 
after organ resection (Figure 3). Both groups showed 
luminescence signals near the transplantation site, which 
increased over time during the experiment (Figure 3A, 
rows 1 and 3). However, additional luminescence signals 
distant from the transplantation site were only observed 
in the control mice (Figure 3A, rows 2 and 4). After the 
sacrifice of the animals, spleens and livers were removed. 
The tumors in the spleens of representative mice and 
the metastatic burden of the corresponding livers are 
shown as luminescence overlays (Figure 3B). Scoring 
of the liver metastases showed a significant decrease 
of number and size of metastases in the animals with 
transplanted HCT116-LUC-shS100A4 cells (P = 0.004). 
Liver metastases of control mice had an average score 
of 27.3 (± 35.1), whereas liver metastases of the mice 
with transplanted HCT116-LUC-shS100A4 cells had an 
average score of 0.3 (± 0.8) (Figure 3C). Quantification 
of bioluminescence signal intensities of organs confirmed 
the reduction of liver metastases with transplanted 
HCT116-LUC-shS100A4 cells (P = 0.035) compared to 
transplanted HCT116-LUC-shNC cells (Figure 3D). No 
significant differences were found in primary tumor size, 
average body weight, as well as the weight of spleens and 
livers (Table 1). The reduction of S100A4 expression in 
tumor tissue of transplanted HCT116-LUC-shS100A4 
mice was verified by qRT‑PCR (Figure 3E). When we 
analyzed changes in the expression of genes associated 
with S100A4-mediated metastasis formation, we observed 
a significant decrease of matrix metalloproteinase 
(MMP) 9 in the tumor tissue derived from HCT116-LUC-
shS100A4 cells (Figure 3F).
Systemic application of S100A4-shRNA 
expression plasmids reduced metastasis formation 
in mice.
In order to evaluate therapeutic approaches to 
interfere with S100A4 driven metastasis formation, we 
improved the experimental setup by systemic application 
of S100A4 shRNA plasmids. First, we determined the 
plasmid copy number of systemically administered shRNA 
expression plasmids (10 µg plasmid DNA) in the blood of 
NOD/SCID mice (n = 5) over time before and 5 minutes, 
30 minutes, as well as 1, 2, 4, and 24 hours after single tail 
vein injection. Although the plasmid is cleared rapidly in 
the blood, 105 copies per µg of total DNA were detectable 
after 24 hours (Figure 4A).
Based on this, the cell line HCT116‑LUC was 
transplanted intrasplenically into female NOD/SCID mice, 
and the animals were randomly divided into two groups 
(n = 8, each). We then applied shRNA expression plasmids 
systemically by repeated tail vein injection every second 
day until day 26. One group was treated with shRNA 
plasmids specific for S100A4, the other with a plasmid 
containing an unrelated control sequence. As we have 
observed before, the in vivo luminescence signals at the 
site of transplantation increased over time in both groups 
(Figure 4B, rows 1 and 3). However, an increase of 
distant, additional signals was mainly observed in control 
mice (Figure 4B, rows 2 and 4). The tumors in the spleens 
of representative mice and the metastatic burden of the 
corresponding livers are shown as ex vivo luminescence 
overlays (Figure 4C). The average score of liver metastases 
in shS100A4 treated animals was also statistically lower, 
compared to control mice, 16.0 (± 14.8) and 59.9 (± 42.6), 
respectively (P = 0.005, Figure 4D). Consistent with our 
previous data, the quantification of bioluminescence signal 
intensities of livers and spleens confirmed the reduction 
in liver metastases in animals treated with S100A4 
shRNA expression plasmids (P = 0.016), compared to a 
treatment with plasmids for control shRNA expression 
(Figure 4E). No significant difference in primary tumor 
size, average body weight or the weight of spleens and 
livers were detectable (Table 1). By plasmid specific 
qPCR, we quantified the copy number of each plasmid 
and determined a similar plasmid concentration of about 
1 x 106 copies per µg of total DNA in primary tumors and 
4 x 106 copies per µg of total DNA in liver metastases, 
respectively, in both animal groups (Figure 4F,G).
Subsequent analysis of relative S100A4 mRNA 
levels in micro-dissected spleen and liver tissue showed 
a significant decrease (P < 0.001) in those animals, 
treated with shS100A4 expression plasmids, to 62% 
in tumors and 50% in metastases of the control mice 
(Figure 5A,B). Again, we found the expression level 
of MMP9 significantly reduced in mice with specific 
S100A4-shRNA treatment. MMP9 mRNA expression 
dropped to 20% (P = 0.037) in spleen tumor tissue 
and to 37% (P = 0.022) in liver metastases, compared 
to control mice (Figure 5C,D). Reduced S100A4 and 
MMP9 expression was confirmed on protein level by 
immunohistochemistry of tumor tissue from both groups 
(Figure 5E,F).
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DISCUSSION
In this study, we demonstrate the reduction 
of S100A4 induced in vivo metastasis formation in 
xenografted colorectal cancer tumors by systemic 
application of plasmids expressing S100A4‑specific 
shRNA, via tail vein injection. The reduced S100A4 
expression resulted in reduced expression of MMP9, 
leading to significantly decreased metastasis formation in 
treated mice.
Administration of naked DNA is a well-established 
tool for gene expression studies in animals as well as 
for gene therapy in clinical trials [26],[27]. Systemic 
application of small inhibiting RNAs, both siRNA and 
shRNA, via tail vein injection leads to an efficient, but 
transient decrease of target gene expression [28], and 
prolonged silencing of target genes has been achieved 
by using shRNA expression plasmids [29],[30]. To 
our knowledge, this is the first study that uses systemic 
application of plasmid based S100A4-shRNA expression 
to inhibit metastasis formation of colorectal cancer.
Growth, signaling, differentiation, and motility are 
susceptible to changes in S100A4 expression [11],[31] 
and the knock-down of S100A4 by RNA interference 
has been reported to inhibit cell growth and motility 
of various cancer cell lines like gastric cancer or 
osteosarcoma [32],[33]. In our study, the stable knock-
down of S100A4 in the colorectal cancer cell lines 
HCT116, SW620, and DLD-1, by plasmid based shRNA 
expression, did not result in reduced cellular growth 
in vitro. This is consistent with studies of other groups, 
that also report no effect of S100A4 reduction on cellular 
growth [21],[22],[34]. Furthermore, by using the recently 
developed impedance based real-time cell analysis, we 
confirmed a decreased migration rate and a decreased 
invasion rate caused by knocked-down S100A4 expression 
in HCT116 cells. In addition, we verified these effects in 
the colorectal cancer cell lines SW620 and DLD-1 by 
classical Boyden chamber assays.
The reduction of cell motility in vitro also suggests 
a decrease in the metastatic potential of S100A4 knock-
down cells in xenografted mice. We transplanted the 
HCT116-LUC-shNC cells into the spleens of NOD/
SCID mice, leading to liver metastases [35]. In contrast, 
transplantation of HCT116-LUC-shS100A4 cells with 
stable down regulation of S100A4 expression resulted 
in significantly less liver metastases in mice. This effect 
has also been shown for RNA interference of S100A4 
expression in osteosarcoma and esophageal squamous cell 
carcinoma, by using stable transfection or siRNA treatment 
previous of cell transplantation, respectively [34].
In vivo data of reduced S100A4 expression in 
colon cancer of other studies were mainly obtained 
by inhibiting the hyperactivated Wnt/β‑catenin 
pathway and therefore indirectly reducing the S100A4 
transcription [5],[17],[19],[20]. Only one S100A4 
protein‑specific peptide inhibitor has been reported so 
far, disrupting the molecular interaction of S100A4 with 
Myosin-IIA [36]. Therefore, we focused on the knock-
down of S100A4 expression by systemic application of 
plasmids for expression of S100A4 specific shRNA.
It was previously shown, that hydrodynamics-
based transfected plasmid DNA in mice is predominantly 
delivered to the liver, but also to spleen, kidney, lung, 
and heart [37]. Moreover, the stable knock-down of gene 
expression by systemic application of shRNA expression 
plasmids seems to be 15 to 250 times more efficient than 
transient knock-down approaches with siRNA [38],[39]. 
In our study, we observed a significant decrease of liver 
metastases to less than 30% of the control group by 
systemic application of S100A4-shRNA expression 
plasmids. This was caused by reduced S100A4 mRNA 
expression in tumors and metastases of human colorectal 
cancer xenografted mice. It also resulted in decreased 
MMP9 mRNA expression in tumors and in metastases. 
The reduction of S100A4 and MMP9 was confirmed 
by immunohistochemistry of tumor tissue samples. The 
role of S100A4 in regulating matrix metalloprotease 
expression and activity has been previously 
reported [14],[40]. In the case of MMP9, several studies 
in different types of cancer report either an increase in 
MMP9 activity with elevated S100A4 expression levels 
or a decrease of MMP9 expression with a knock-down 
of S100A4 [15],[41–44] One possible mechanism, 
which is discussed for the S100A4 dependent MMP9 
regulation, is the direct or indirect activation of p53 or 
JNK, since S100A4 is a binding partner of p53 and can 
modulate its activity [45],[46]. An additional mechanism 
may include the interaction of S100A4 with Smad3, a 
member of the TGF‑β/Smad pathway, which also regulates 
MMP9 expression [44],[47]. The complexity of protein 
interactions and regulated pathways might be dependent 
on the tumor entity and requires further investigations to 
understand tissue specific metastasis promoting factors.
Since 40% of colorectal cancer patients form distant 
metastases after initial resection of the primary tumor, 
the development of adjuvant anti‑metastatic treatment 
options is needed [48]. Here we demonstrate for the first 
time that the systemic application of plasmid DNA for 
S100A4‑specific shRNA decreased S100A4 and MMP9 
expression levels in tumors and metastases, and, most 
importantly, reduced formation of liver metastasis. Thus, 
a personalized RNA interference approach to reduce the 
S100A4 expression in those patients with high S100A4 
expressing primary tumors might serve as an alternative 
or addition to adjuvant chemotherapeutic protocols for 
prevention of metastasis formation in colorectal cancer.
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METHODS
Ethics statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors’ 
institutional review board.
Cell culture and transfection
The human colorectal cancer cell line HCT116 
was stably transfected with a pcDNA3.1 plasmid, 
carrying firefly luciferase under the CMV promoter, 
and the puromycin resistance cassette [19]. The 
resulting cell line HCT116-LUC was further transfected 
with SureSilencing™ control or S100A4 shRNA 
expression plasmids, containing the neomycin 
resistance cassette (SABiosciences, Frederick, 
MD). HCT116-LUC-shS100A4 cells express a 
shRNA, specifically targeting S100A4‑mRNA, while 
HCT116-LUC-shNC cells (negative control) express an 
unrelated control sequence. Transfection of the cell lines 
SW620 and DLD-1 with the shRNA-expression plasmids 
resulted in the cell lines SW620-shS100A4, SW620-shNC, 
DLD-1-shS100A4, and DLD-1-shNC, respectively. All 
transfections were performed with Fugene HD (Roche 
Diagnostics, Germany), according to the manufacturer’s 
instructions. Transfected cells were selected with 1 mg/
ml neomycin (PAA Laboratories, Austria) or 1 µg/ml 
puromycin (Life Technologies Corporation, Carlsbad, 
CA). All cell lines derived from HCT116 and SW620 were 
grown in RPMI-1640 medium, cell lines derived from 
DLD-1 were grown in DMEM (PAA Laboratories), each 
medium supplemented with 10% FCS (Life Technologies 
Corporation), in a humidified incubator at 37°C and 
5% CO2. The cell lines were tested with the MycoAlert® 
Mycoplasma Detection Kit (Lonza, Rockland, ME), and 
found to be free of mycoplasma. The genotype of the 
parental cell lines HCT116, SW620, and DLD-1 were 
confirmed by short tandem repeat (STR) genotyping at the 
DSMZ (German Collection of Microorganisms and Cell 
Cultures; Braunschweig, Germany). The STR genotypes 
were consistent with published genotypes for each cell 
line.
Real-time Quantitative Reverse Transcriptase 
Polymerase Chain Reaction (qRT-PCR)
Total RNA from cell culture or tissues was isolated 
using the Universal RNA Purification Kit (Roboklon, 
Germany), according to the manufacturer’s instructions. 
Quantification of RNA concentration was performed with 
Nanodrop (Peqlab, Germany), and 50 ng total RNA was 
reverse transcribed with random hexamers in a reaction 
mix (10 mM MgCl2, 1 × PCR-buffer II, 250 µM pooled 
dNTPs, 1 U/µL RNAse inhibitor, 2.5 U/µL MuLV reverse 
transcriptase; all from Life Technologies Corporation). 
Reaction occurred at 42°C for 15 minutes, 95°C for 
5 minutes, and subsequent cooling at 4°C for 5 minutes. 
The cDNA product was amplified in a total volume of 
10 µl in 96-well plates using the LightCycler 480 (Roche 
Diagnostics, Mannheim, Germany) and the following PCR 
conditions: 95°C for 10 minutes, followed by 45 cycles of 
95°C for 10 seconds, 60°C for 30 seconds, and 72°C for 
4 seconds. For S100A4 cDNA quantification, the following 
primer and probes were used for a 124 bp amplicon: 
forward primer, 5′‑gagctgcccagcttcttg‑3′; reverse primer, 
5´‑tgcaggacaggaagacacag‑3´; fluorescein isothiocyanate 
(FITC) probe, 5′‑tgatgagcaacttggacagcaaca‑3′; and 
LCRed640‑probe, 5′‑gacaacgaggtggacttccaagagt‑3′. For 
cDNA quantification of the housekeeping gene glucose‑
6-phosphate dehydrogenase (G6PDH) the LightCycler-h-
G6PDH Housekeeping Gene Set (Roche Diagnostics) was 
used, according to manufacturer’s instructions, leading to 
a 113 bp amplicon. For MMP9 and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) cDNA quantification 
with a SYBR® Green based reaction mix (GoTaq®; 
Promega, Germany), the following primers were used: 
MMP9, forward-primer 5´-tggggggcaactcggc-3´, reverse-
primer 5´-ggaatgatctaagcccag-3´, 224 bp amplicon; 
GAPDH, forward-primer 5´-gaaggtgaaggtcggagtc-3´, 
reverse-primer 5´-ggtggaatcatattggaacatgtaa-3´, 
151 bp amplicon. Data analysis was performed with 
LightCycler 480 Software release 1.5.0 SP3 (Roche 
Diagnostics). Mean values were calculated from duplicate 
qRT-PCR reactions. Each mean value of the expressed 
gene was normalized to the respective mean value of the 
housekeeping gene cDNA. The cDNA for the calibrator 
and the in-run standard derived from HCT116 cells was 
employed in serial dilutions simultaneously in each run.
Protein extraction and immunoblot
For total protein extraction, cells were lysed 
with RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 
1% Nonidet P-40, supplemented with complete protease 
inhibitor tablets; Roche Diagnostics) for 30 minutes on 
ice. Protein concentration was quantified with Coomassie 
Plus (Bradford) Protein Assay Reagent (Pierce; Rockford, 
IL), according to manufacturer’s instructions, and lysates 
of equal protein concentration were separated with SDS-
PAGE and transferred to Hybond-C Extra nitrocellulose 
membrane (GE Healthcare; Germany). Membranes were 
incubated in blocking solution containing 5% nonfat dry 
milk for 1 hour at room temperature. Membranes were 
incubated overnight at 4°C with rabbit anti‑human S100A4 
antibody (Dako, Denmark; dilution 1:1000) or goat anti-
Oncotarget 2012; 3: 783-797793www.impactjournals.com/oncotarget
human GAPDH antibody (Santa Cruz Biotechnology; 
dilution 1:500) followed by incubation for 1 hour at room 
temperature with HRP‑conjugated anti‑rabbit IgG (dilution 
1:10000) or anti-goat IgG (dilution 1:10000), respectively. 
Antibody-protein-complexes were visualized with 
electrochemical-luminescence reagent (100 mM Tris/HCl, 
0.025% w/v luminol, 0.011% w/v para-hydroxycoumaric 
acid, 10% v/v dimethylsulfoxide, 0.004% v/v H2O2, 
pH 8.6) and subsequent exposure to CL-XPosure™ Films 
(Pierce). Immunoblotting for GAPDH served as protein 
loading control. All experiments were performed at least 
three independent times.
Immunocytochemistry and immunohistochemistry
For immunocytochemistry, cells were cultured 
on double-chamber slides (Nunc, Rochester, NY). For 
immunohistochemistry, cryosections (5 µm) of tumor 
tissue were transferred onto glass slides. Samples were 
fixated for 15 minutes with 0.04% glutaraldehyde, 
endogenous peroxidase was inactivated for 20 minutes 
with 0.9% H2O2, and cells were permeabilized for 
10 minutes with 0.5% Triton X100 in 2.5% BSA. After 
blocking for 1 hour with 5% BSA, cells were incubated 
with the S100A4 antibody (dilution 1:400, 2 hours) or 
rabbit h-MMP9 antibody (Cell Signaling, dilution 1:400, 
2 hours). Detection was performed using the biotin-
based ABC kit (Dako, Denmark) and diaminobenzidine 
as substrate, according to manufacturer’s instructions. 
Positive signals resulted in brown staining. The slides 
were counterstained with haematoxylin and analyzed 
using a light microscope Axioplan2 (Leica, Germany) at a 
magnification of 40x. Negative control experiments were 
carried out by omitting the primary antibody.
Real-time electrical impedance–based monitoring 
of cell migration, invasion and proliferation
For monitoring of cell migration and invasion in 
real-time the xCELLigence Real Time Cell Analyzer 
Dual Plate (RTCA-DP) instrument was used according 
to the manufacturer’s recommendations (Roche Applied 
Science, Germany). The impedance is expressed as 
a dimensionless parameter, termed cell index, and is 
directly proportional to the area covered by cells. For 
detection of cellular migration and invasion, electrical 
impedance changes are measured at a gold microelectrode 
plated on the bottom of a membrane separating the 
upper and lower chambers. The cell line (HCT116-LUC) 
and the clones expressing control- or S100A4-shRNA 
(HCT116-LUC-shNC and HCT116-LUC-shS100A4, 
respectively) were subjected to serum starvation, 12 hours 
before the start of measurement. For cell migration assays, 
5 x 104 cells in RPMI-1640 were seeded per well of a 
16-well CIM plate, and the lower chamber was loaded 
with RPMI-1640, supplemented with 10% FCS. For 
cell invasion assays, the membranes were coated with 
Matrigel (dilution 1:40 with medium) 12 hours before 
seeding 1 x 105 cells. Cell proliferation was determined 
by seeding 5 x 103 cells per well into E-Plates and 
recording the cell index every 15 minutes for 75 hours. 
Quantitative measurements of changes of the electrical 
impedance are expressed as cell index. For cell migration, 
cell index values were monitored every 5 minutes for 
24 hours. For invasion, the cell index was measured 
every 15 minutes for 48 hours. At least three independent 
experiments were performed for monitoring cell migration 
or invasion, respectively, each carried out in triplicates. 
Cell index values were calculated and plotted using the 
RTCA software 1.2.1 of the RTCA xCELLigence system. 
For cell migration, the cell index curves were normalized 
2 hours after seeding and signals between 2 hours and 
8 hours were used to calculate the area under the curve. 
For cell invasion, the cell index curves were normalized 
12 hours after seeding and signals between 12 hours and 
36 hours were used to calculate the area under the curves. 
Average values were normalized to HCT116-LUC.
Wound healing assay
Wound healing assay was performed as described 
previously [19]. HCT116-LUC, HCT116-LUC-shNC 
and HCT116-LUC-shS100A4 cells were grown to 
form 60% confluent monolayers, in which a wound of 
about 0.3 mm width was set with a sterile pipette tip. 
The medium was exchanged to remove non-adherent 
cells. The progress of wound closure was monitored 
daily with microphotographs of 10 × magnification 
taken with the Leica DM IL light microscope and a 
Kappa CF 15/4 MCC-MLUII Modul camera (Leica 
Microsystems) up to day 4. The wound healing experiment 
was performed three independent times. The spreading of 
cells across the area of the wound at day 4 was quantified 
with ImageJ [49]. The background value (day 1) was 
substracted and the average values were normalized to 
HCT116-LUC.
Monitoring cell proliferation by MTT
Two x 103 cells of the cell lines SW620 and DLD-
1, including the stable shRNA expression clones SW620-
shNC, SW620-shS100A4, DLD-1-shNC and DLD-1-
shS100A4, respectively, were seeded in 96-well-plates 
(for each day one plate) and incubated for 24 hours 
to allow the cells to attach to the bottom of the wells. 
Determination of viable cells was performed by adding 
3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT; Sigma‑Aldrich) to a final concentration of 
0.5 mg/ml. After 3 hours incubation at 37°C and 5% CO2 
in a humidified incubator, the formazan crystals were 
resolved by 10% SDS in 10 mM HCl and the absorption 
was measured at 560 nm. MTT measurements were 
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performed daily for 5 consecutive days, as triplicates in 
three independent experiments. The absorption data were 
used to calculate the doubling time of each cell line (V. 
Roth 2006; wwww.doubling-time.com).
Colony formation assay
Anchorage-independent cell proliferation 
was analyzed by soft agar colony formation 
assay. HCT116-LUC, HCT116-LUC-shNC and 
HCT116-LUC-shS100A4 cells were resuspended 
in RPMI-1640, supplemented with 10% FCS and 
0.33% (w/v) agarose (Life Sciences Corporation). One 
x 103 cells/ml were seeded into soft agar and colony 
growth was analyzed after 7 days by light microscopy. 
Only colonies with more than three cells were counted. 
Independent colony formation experiments were repeated 
twice, each in triplicate.
Boyden chamber transwell migration and 
invasion assay
The cell lines HCT116-LUC, SW620, and DLD-1 
and the respective clones expressing control- or S100A4-
shRNA were used in cell migration and invasion analyses 
performed with Boyden chamber assay. 2.5 × 105 cells 
were seeded into each transwell chamber with filter 
membranes of 12 μm pore size (Millipore, Germany). 
For invasion, filter membranes were coated with Matrigel 
(BD Biosciences; diluted 1:3 in growth medium) 4 hours 
before cell seeding, and fresh medium was added to the 
bottom chamber. After 24 hours (migration) or 72 hours 
(invasion), respectively, insets were removed and cells, 
which had migrated through the membrane to the lower 
chamber, were trypsinized and counted in a Neubauer 
chamber (LO‑Laboroptik, Bad Homburg, Germany). Each 
well was counted ten times. Each migration or invasion 
experiment was performed in duplicate. The average 
number of migrated or invaded cells was determined from 
at least three independent experiments.
Monitoring plasmid concentration in mouse blood 
after tail vein injection
Plasmid concentration in the blood of NOD/
SCID mice after single tail vein injection of 10 µg 
SureSilencing™ shRNA expression plasmid (QIAGEN, 
Germany), supplemented with 2 µg aurintricarbolic acid 
(Sigma, Germany) in 200 µl sterile PBS, were determined 
by total DNA extraction of 200 µl blood samples (Quick 
Blood DNA Extraction Kit; Roboklon, Germany), taken 
before single tail vein injection and after 5 minutes, 
30 minutes, 1, 2, 4,  and 24 hours. Plasmid copy numbers 
were determined by SYBR Green based quantitative real 
time PCR (forward-primer 5´-agacaatcggctgctctgat-3´, 
reverse-primer 5´-caatagcagccagtcccttc-3´, 203 bp 
amplicon).
Metastasis formation in xenografted mice
Animal experiments were performed in accordance 
with the UKCCCR guidelines and approved by the 
responsible local authorities (State Office of Health and 
Social Affairs, Berlin, Germany). For analysis of stably 
transfected shRNA-expressing cell lines, 3 x 106 cells 
HCT116-LUC-shNC or HCT116-LUC-shS100A4 were 
transplanted at day zero into the spleens of 6 to 8 weeks 
old female NOD/SCID mice (randomly assigned to 
8 mice per group). The mice were imaged twice a week 
in a NightOWL LB 981 system (Berthold Technologies, 
Germany) by intraperitoneal injection of 150 mg/kg 
D‑luciferin (Biosynth, Switzerland) under temporal 
anesthesia with 35 mg/kg hypnomidate (Jassen-Cilag, 
Germany). Mice were sacrificed at day 28. Spleens (site 
of tumor injection) and livers (metastasis target organ) 
were removed and shock-frozen in liquid nitrogen. To 
evaluate systemic application of shRNA-expressing 
plasmids, 3 x 106 HCT116-LUC cells were transplanted at 
day zero into the spleens of 6 to 8 weeks old female NOD/
SCID mice (randomly assigned to 8 mice per group). 
Ten µg SureSilencing™ shRNA expression plasmid 
(SABiosciences), containing either S100A4‑specific 
(shS100A4) or negative control (shNC) shRNA sequences, 
respectively, supplemented with 2 µg aurintricarbolic acid 
in 200 µl sterile PBS, were injected within 1 second into 
the tail vein at days 1, 5, 7, 9, 12, 14, 16, 19, 21, 23, and 
26. The mice were imaged twice a week, as described 
above. Mice were sacrificed at day 27. Spleens and 
livers were removed and shock-frozen in liquid nitrogen. 
The level of liver metastasis was evaluated by scoring. 
The score for each liver was calculated as the sum of 
the volumes V of the individual metastases, calculated 
by V=L2 x W (with L as the length of the smaller axis, 
and W as the length of the larger axis). Luminescence 
signals of isolated organs were quantified with ImageJ. 
Serial consecutive cryosections were made from spleen 
tumors and liver metastases for immunohistochemistry or 
subsequent DNA and RNA isolations.
Statistical analysis
Statistical analyses were performed with Sigma 
Stat Version 3.5. Depending on the normal distribution 
of the dataset, comparison of two groups was done either 
by Student’s t-test or Mann-Whitney-Rank-Sum-Test. 
Comparison of more than two groups was performed by 
one‑way analysis of variance (ANOVA) and Bonferroni 
post hoc multiple comparison. P values less than 0.05 
were defined as statistically significant.
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